Endocyte, Inc. – Product Pipeline Review – Q2 2011
Reference Code: GMDHC1284CDB
Publication Date: JULY 2011
Endocyte, Inc. – Product Pipeline Review – Q2 2011 GMDHC1284CDB / Published JULY 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Endocyte, Inc. – Product Pipeline Review
Ta b le o f Co n te n ts
Table of Contents 2
List of Tables 4
List of Figures 5
Endocyte, Inc. Snapshot 6
Endocyte, Inc. Overview 6
Key Information 6
Key Facts 6
Endocyte, Inc. – Research and Development Overview 7
Key Therapeutic Areas 7
Endocyte, Inc. – Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products – Monotherapy 11
Pipeline Products – Combination Treatment Modalities 12
Endocyte, Inc. – Pipeline Products Glance 13
Endocyte, Inc. – Late Stage Pipeline 13
Phase III Products/Combination Treatment Modalities 13
Endocyte, Inc. Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
Endocyte, Inc.–Early Stage Pipeline Products 15
Pre-Clinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Endocyte, Inc. – Drug Profiles 17
EC145 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
EC145 + Doxil 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
EC0225 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
EC0489 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
EC0482 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
EC0531 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Endocyte, Inc. – Product Pipeline Review – Q2 2011 GMDHC1284CDB / Published JULY 2011
©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(2)
Endocyte, Inc. – Product Pipeline Review
EC0565 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
EC0746 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
EC1069 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ECO531 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
EC0845 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Endocyte, Inc. – Pipeline Analysis 28
Endocyte, Inc. – Pipeline Products by Therapeutic Class 28
Endocyte, Inc. - Pipeline Products By Target 30
Endocyte, Inc. – Pipeline Products by Route of Administration 31
Endocyte, Inc. – Pipeline Products by Molecule Type 32
Endocyte, Inc. – Recent Pipeline Updates 33
Endocyte, Inc. - Dormant Projects 34
Endocyte, Inc. - Discontinued Pipeline Products 35
Discontinued Pipeline Product Profiles 35
EC17 35
EC90 + EC17+ GPI-0100 + IL-2 + IFN-alpha 35
Endocyte, Inc. – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Financial Deals Landscape 37
Endocyte, Inc., Deals Volume Summary, 2004 to YTD 2011 37
Endocyte, Inc., Deals Summary By Region, 2004 to YTD 2011 38
Endocyte, Inc., Deals Summary, 2004 to YTD 2011 39
Endocyte, Inc. Detailed Deal Summary 40
Venture Financing 40
Endocyte Secures $26 Million In Series C-4 Round 40
Endocyte Secures $15 Million In Series C-3 Financing 42
Endocyte Secures $23 Million In Series C-2 Fin